» Articles » PMID: 20162425

Lead Time of Carcinoembryonic Antigen Elevation in the Postoperative Follow-up of Colorectal Cancer Did Not Affect the Survival Rate After Recurrence

Overview
Date 2010 Feb 18
PMID 20162425
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The role of carcinoembryonic antigen (CEA) in the early detection of recurrence during the postoperative follow-up of colorectal cancer remains unclear. We hypothesize that the tumor with longer lead time of CEA elevation to the definite recurrence may have a better prognosis because of its slower growth rate and closer observation.

Materials And Methods: From 1995 to 2003, 4,841 consecutive patients who received curative resection of localized colorectal adenocarcinoma were enrolled from a prospective database. The patients with persisting CEA elevation after operation had been already excluded. Postoperative follow-up, including physical examination, imaging, and CEA test, were performed according to a surveillance program. A CEA >/=5 ng/mL was defined as elevated. The definition of the CEA lead time was the period between CEA elevation and detection of recurrence. All statistical analyses were performed by SPSS package for Windows (Microsoft, Redmond, WA, USA).

Results: The postoperative median follow-up time for the 4,841 patients was 68 months. A total of 999 patients (20.6%) had CEA elevation and recurrence. Among these patients, recurrence was confirmed in 727 patients (72.8%)before, at the same time, or within 3 months of CEA elevation and thus had a short lead time of CEA elevation (SLT group). In 272 patients (27.2%), recurrence was confirmed after more than 3 months of CEA elevation and thus had a longer lead time of CEA elevation (LLT group). The recurrence pattern showed similarities in these two groups. A total of 193 patients (193/999, 19.3%) received a second radical operation, and 806 patients (80.7%) were inoperable. The re-resection rate between the SLT group (146 patients, 20.1%) and the LLT group (47 patients, 17.3%) was not significantly different. The overall survival rate after recurrence showed no difference between these two groups (P = 0.123).

Conclusion: Most cases of recurrence were detected at nearly the same time when the CEA level was elevated. Therefore, a more sensitive test is needed for early detection. The relationship between the lead time of CEA and the clinical outcome was not statistically significant. A more aggressive approach to the patient who has CEA elevation and is highly suspect of recurrence may be needed.

Citing Articles

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.

Lehtomaki K, Mustonen H, Kellokumpu-Lehtinen P, Joensuu H, Hermunen K, Soveri L Cancers (Basel). 2021; 13(15).

PMID: 34359796 PMC: 8345682. DOI: 10.3390/cancers13153892.


Clinical Significance of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Follow-up of Colorectal Cancer: Searching off Approaches Increasing Specificity for Detection of Recurrence.

Ince S, Okuyucu K, Hancerliogullari O, Alagoz E, San H, Arslan N Radiol Oncol. 2018; 51(4):378-385.

PMID: 29333115 PMC: 5765313. DOI: 10.1515/raon-2017-0045.


Evaluation of recurrent disease in the re-staging of colorectal cancer by F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection.

Chiaravalloti A, Fiorentini A, Palombo E, Rinino D, Lacanfora A, Danieli R Oncol Lett. 2016; 12(5):4209-4213.

PMID: 27895793 PMC: 5104254. DOI: 10.3892/ol.2016.5143.


The prognostic significance and treatment modality for elevated pre- and postoperative serum CEA in colorectal cancer patients.

Yang K, Park I, Kim C, Roh S, Cho D, Kim J Ann Surg Treat Res. 2016; 91(4):165-171.

PMID: 27757393 PMC: 5064226. DOI: 10.4174/astr.2016.91.4.165.


Elevated Serum Carcinoembryonic Antigen Is Associated with a Worse Survival Outcome of Patients After Liver Resection for Hepatocellular Carcinoma: a Propensity Score Matching Analysis.

Liu J, Xia Y, Shi L, Li X, Wu L, Yan Z J Gastrointest Surg. 2016; 20(12):2063-2073.

PMID: 27730399 DOI: 10.1007/s11605-016-3295-8.


References
1.
MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Tangen C . An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993; 270(8):943-7. View

2.
Staab H, Anderer F, Stumpf E, Hornung A, Fischer R, Kieninger G . Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg. 1985; 149(2):198-204. DOI: 10.1016/s0002-9610(85)80064-7. View

3.
Gold P, Freedman S . DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med. 1965; 121:439-62. PMC: 2137957. DOI: 10.1084/jem.121.3.439. View

4.
Korner H, Soreide K, Stokkeland P, Soreide J . Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol. 2006; 14(2):417-23. DOI: 10.1245/s10434-006-9060-6. View

5.
Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C . Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer. 2006; 118(12):3072-7. DOI: 10.1002/ijc.21784. View